Therapeutic drug monitoring of flucytosine in a cardiac transplant patient receiving continuous veno‐venous hemofiltration and intermittent hemodialysis: A case report

Invasive candidiasis is one of the common infections in solid organ transplant recipients. Guidelines recommend echinocandins or liposomal amphotericin with consideration of flucytosine (5‐fluorocytosine; 5‐FC) as synergistic therapy for treatment of select deep‐seated Candida infections, including...

Full description

Saved in:
Bibliographic Details
Published in:Transplant infectious disease 2021-08, Vol.23 (4), p.e13575-n/a
Main Authors: Williams, Kelsey N., Bidell, Monique R., Adamsick, Meagan L., Elshaboury, Ramy H., Roberts, Matthew B., Kotton, Camille N., Gandhi, Ronak G.
Format: Article
Language:English
Subjects:
antifungals
Candidiasis
Cardiovascular system
Case reports
Dosage
Drug dosages
Echinocandins
Flucytosine
Fungemia
Heart transplantation
Hemodialysis
Infections
infectious diseases
Mediastinitis
Monitoring
Patients
pharmacokinetics
Renal function
Telemedicine
Therapeutic drug monitoring
transplant
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Invasive candidiasis is one of the common infections in solid organ transplant recipients. Guidelines recommend echinocandins or liposomal amphotericin with consideration of flucytosine (5‐fluorocytosine; 5‐FC) as synergistic therapy for treatment of select deep‐seated Candida infections, including complex endovascular infections. Flucytosine undergoes extensive renal elimination; however, optimal dosing in patients with renal impairment, or those requiring renal replacement therapy (RRT), is not well‐established. We describe a case of a 60‐year old female who underwent orthotopic heart transplant complicated by Candida parapsilosis complex fungemia with mediastinitis and development of end‐stage renal disease requiring RRT. Flucytosine therapeutic drug monitoring was performed on continuous veno‐venous hemofiltration (CVVH) and intermittent hemodialysis (iHD) to guide appropriate dosing. Our results support 5‐FC doses of 25 mg/kg daily while undergoing CVVH with a low fluid replacement rate and 21 mg/kg post‐iHD or 17 mg/kg daily while receiving thrice weekly iHD.
ISSN:1398-2273
1399-3062
DOI:10.1111/tid.13575